Cargando…
A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans
Low intensity transcranial focused ultrasound (LIFU) is a promising method of non-invasive neuromodulation that uses mechanical energy to affect neuronal excitability. LIFU confers high spatial resolution and adjustable focal lengths for precise neuromodulation of discrete regions in the human brain...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101402/ https://www.ncbi.nlm.nih.gov/pubmed/32221350 http://dx.doi.org/10.1038/s41598-020-62265-8 |
_version_ | 1783511616245989376 |
---|---|
author | Legon, Wynn Adams, Sarah Bansal, Priya Patel, Parantap D. Hobbs, Landon Ai, Leo Mueller, Jerel K. Meekins, Gregg Gillick, Bernadette T. |
author_facet | Legon, Wynn Adams, Sarah Bansal, Priya Patel, Parantap D. Hobbs, Landon Ai, Leo Mueller, Jerel K. Meekins, Gregg Gillick, Bernadette T. |
author_sort | Legon, Wynn |
collection | PubMed |
description | Low intensity transcranial focused ultrasound (LIFU) is a promising method of non-invasive neuromodulation that uses mechanical energy to affect neuronal excitability. LIFU confers high spatial resolution and adjustable focal lengths for precise neuromodulation of discrete regions in the human brain. Before the full potential of low intensity ultrasound for research and clinical application can be investigated, data on the safety of this technique is indicated. Here, we provide an evaluation of the safety of LIFU for human neuromodulation through participant report and neurological assessment with a comparison of symptomology to other forms of non-invasive brain stimulation. Participants (N = 120) that were enrolled in one of seven human ultrasound neuromodulation studies in one laboratory at the University of Minnesota (2015–2017) were queried to complete a follow-up Participant Report of Symptoms questionnaire assessing their self-reported experience and tolerance to participation in LIFU research (I(sppa) 11.56–17.12 W/cm(2)) and the perceived relation of symptoms to LIFU. A total of 64/120 participant (53%) responded to follow-up requests to complete the Participant Report of Symptoms questionnaire. None of the participants experienced serious adverse effects. From the post-hoc assessment of safety using the questionnaire, 7/64 reported mild to moderate symptoms, that were perceived as ‘possibly’ or ‘probably’ related to participation in LIFU experiments. These reports included neck pain, problems with attention, muscle twitches and anxiety. The most common unrelated symptoms included sleepiness and neck pain. There were initial transient reports of mild neck pain, scalp tingling and headache that were extinguished upon follow-up. No new symptoms were reported upon follow up out to 1 month. The profile and incidence of symptoms looks to be similar to other forms of non-invasive brain stimulation. |
format | Online Article Text |
id | pubmed-7101402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-71014022020-03-31 A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans Legon, Wynn Adams, Sarah Bansal, Priya Patel, Parantap D. Hobbs, Landon Ai, Leo Mueller, Jerel K. Meekins, Gregg Gillick, Bernadette T. Sci Rep Article Low intensity transcranial focused ultrasound (LIFU) is a promising method of non-invasive neuromodulation that uses mechanical energy to affect neuronal excitability. LIFU confers high spatial resolution and adjustable focal lengths for precise neuromodulation of discrete regions in the human brain. Before the full potential of low intensity ultrasound for research and clinical application can be investigated, data on the safety of this technique is indicated. Here, we provide an evaluation of the safety of LIFU for human neuromodulation through participant report and neurological assessment with a comparison of symptomology to other forms of non-invasive brain stimulation. Participants (N = 120) that were enrolled in one of seven human ultrasound neuromodulation studies in one laboratory at the University of Minnesota (2015–2017) were queried to complete a follow-up Participant Report of Symptoms questionnaire assessing their self-reported experience and tolerance to participation in LIFU research (I(sppa) 11.56–17.12 W/cm(2)) and the perceived relation of symptoms to LIFU. A total of 64/120 participant (53%) responded to follow-up requests to complete the Participant Report of Symptoms questionnaire. None of the participants experienced serious adverse effects. From the post-hoc assessment of safety using the questionnaire, 7/64 reported mild to moderate symptoms, that were perceived as ‘possibly’ or ‘probably’ related to participation in LIFU experiments. These reports included neck pain, problems with attention, muscle twitches and anxiety. The most common unrelated symptoms included sleepiness and neck pain. There were initial transient reports of mild neck pain, scalp tingling and headache that were extinguished upon follow-up. No new symptoms were reported upon follow up out to 1 month. The profile and incidence of symptoms looks to be similar to other forms of non-invasive brain stimulation. Nature Publishing Group UK 2020-03-27 /pmc/articles/PMC7101402/ /pubmed/32221350 http://dx.doi.org/10.1038/s41598-020-62265-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Legon, Wynn Adams, Sarah Bansal, Priya Patel, Parantap D. Hobbs, Landon Ai, Leo Mueller, Jerel K. Meekins, Gregg Gillick, Bernadette T. A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans |
title | A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans |
title_full | A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans |
title_fullStr | A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans |
title_full_unstemmed | A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans |
title_short | A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans |
title_sort | retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101402/ https://www.ncbi.nlm.nih.gov/pubmed/32221350 http://dx.doi.org/10.1038/s41598-020-62265-8 |
work_keys_str_mv | AT legonwynn aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT adamssarah aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT bansalpriya aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT patelparantapd aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT hobbslandon aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT aileo aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT muellerjerelk aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT meekinsgregg aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT gillickbernadettet aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT legonwynn retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT adamssarah retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT bansalpriya retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT patelparantapd retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT hobbslandon retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT aileo retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT muellerjerelk retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT meekinsgregg retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans AT gillickbernadettet retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans |